Lenalidomide in multiple myeloma-a practice guideline

Current Oncology

Volumn 20, Issue 2, 2013, Pages

  Chen, C ^a   Baldassarre, Fulvia ^b   Kanjeekal, S ^c   Herst, J ^d   Hicks, L ^e   Cheung, M ^f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Centre Regional De Cancerologie De Windsor   (Canada)

^d HEALTH SCIENCES NORTH   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

IMiD; Lenalidomide; Multiple myeloma; Practice guideline

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; INFECTION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 84875904689     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1252     Document Type: Article

References (67)

1. Weber DM, Chen C, Niesvizky R, et al. on behalf of the Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.
2. Dimopoulos M, Spencer A, Attal M, et al. on behalf of the Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
3. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
4. Lyman GH, Khorana AA, Falanga A, et al. on behalf of the American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
5. National Institute for Health and Clinical Excellence (nice). Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. London, UK: nice; 2009. [Available online at: http://www.nice.org.uk/nicemedia/pdf/TA171Guidance.pdf; cited December 15, 2011]
6. Richardson P, Mitsiades C, Laubach J, et al. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid 2010;4:215-45.
7. Boen M, McKoy J, West D, et al. Thalidomide (thal), le-nalidomide (len), and dexamethasone (dex)-associated venousthromboembolism (vte) and reported vte rates pre-and post-fda approval: optimal prophylaxis strategies are still unclear [abstract]. Blood 2008;112:A2403.
8. Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9:653-63.
9. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-41.
10. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
11. Richardson PG, Blood E, Mitsiades CS, et al. A random-ized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
12. Richardson PGG, Moreau P, Jakubowiak AJ, et al. Elotu-zumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: a randomized phase ii study [abstract 8014]. J Clin Oncol 2011;29:. [Avail-able online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=102&?abstractID=80348; cited January 10, 2013]
13. Kumar A, Flinn I, Richardson P, et al. Final results from the multi-center, randomized, phase 2 evolution study of combi-nations of bortezomib (v), dexamethasone (d), cyclophospha-mide (c), and lenalidomide (r) in previously untreated multiple myeloma (mm). Haematologica 2011;96(suppl 1):S100.
14. Attal M, Olivier P, Lauwers VC, et al. Maintenance treat-ment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial [abstract]. Haematologica 2011;96(suppl 1):S23.
15. 2) and autologous transplantation in newly diagnosed myeloma patients: a phase iii trial [abstract O272]. Bone Marrow Transplant 2011;46(suppl 1):S38.
16. Zangari M, Barlogie B, Jacobson J, et al. Revlimid 25 mg (REV 25) × 20 versus 50 mg (REV 50) × 10 q 28 days with bridging of 5 mg × 10 versus 10 mg × 5 as post-transplant salvage therapy for multiple myeloma [abstract 1642]. Blood 2003;102:1642.
17. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010;28:132-5.
18. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010;116:3807-14.
19. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738-44.
20. Castaneda C, Weiss L, Minton NA, et al. Peripheral neuropa-thy in multiple myeloma patients treated with lenalidomide [abstract 5024]. Blood 2010;116:5024.
21. Baz R, Lonial S, Hussein M, Swern AS, Dimopoulos MA. Lenalidomide (len) therapy in combination with dexametha-sone (dex) is associated with a low incidence of viral infections [abstract 1950]. Blood 2010;116:1950.
22. Baz R, Dimopoulos M, Richardson P, Yu Z, Hussein M, Chanan-Khan A. Lenalidomide-based therapy leads to improvement of humoral immune system in relapsed or re-fractory multiple myeloma patients who respond to therapy [abstract 0395]. Haematologica 2009;94(suppl 2):159.
23. Lonial S, Baz R, Swern AS, Weber D, Dimopoulos MA. Neutropenia is a predictable and early event in affected pa-tients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone [abstract 2978]. Blood 2009;114:2878.
24. Delforge M, Facon T, Bravo ML, Dimopoulos MA. Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy [abstract 3873]. Blood 2009;114:A3873.
25. Dimopoulos MA, Hussein M, Swern AS, Weber D. Full dose of lenalidomide for 12 months followed by a lower mainte-nance dose improves progression-free survival in patients with relapsed/refractory multiple myeloma [abstract 2874]. Blood 2009;114:2874.
26. Dimopoulos MA, Anagnostopoulos A, Prince M, et al. Lenalidomide (Revlimid) combination with dexamethasone (Dex) is more effective than Dex alone in patients with re-lapsed or refractory multiple myeloma and independent of number of previous treatments [abstract 0494]. Haematologica 2006;91(suppl 1):181.
27. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase iii trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52.
28. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regard-less of prior thalidomide exposure. Blood 2008;112:4445-51.
29. Hazarika M, Rock E, Williams G, et al. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist 2008;13:1120-7.
30. San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Ef-fects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:38-43.
31. Simpson L, Rajkumar SV, Dispenzieri A, et al. High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma [abstract 8586]. J Clin Oncol 2008;26(suppl 15):. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=55&abstractID=35993; cited Janu-ary 12, 2013]
32. Foa R, Weber D, Dimopoulos M, et al. Lenalidomide/dexamethasone improves response and prolongs time toprogression, even in patients with IgA multiple myeloma: a sub-analysis of the MM-009/010 studies [abstract 284b]. Blood 2007;110:284b.
33. San Miguel JF, Dimopoulos M, Weber D, et al. Dexametha-sone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis) [abstract]. Blood 2007;110:2712.
34. Lonial S, Knight R, Dimopolous M, et al. Effect of len/dex in mm in different age groups [abstract]. Hematologica 2007;92(suppl 2);171.
35. Chanan-Khan A, Weber D, Dimopolous M, et al. Lenalido-mide (l) in combination with dexamethasone (d) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (mm) [abstract 3553]. Blood 2006;108:1014.
36. Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (l) in combination with dexamethasone (d) significantly improves time to progression (ttp) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (mm): analysis from MM-009 and MM-010 randomized phase iii clinical trials. Blood 2006;108:1015.
37. Chanan-Khan AA, Dimopoulos M, Weber D, et al. ecog performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 sub-analysis) [abstract 2721]. Blood 2007;110:2721.
38. Niesvizky R, Spencer A, Wang M, et al. Increased risk of thrombosis with lenalidomide in combination with dexa-methasone and erythropoietin [abstract 7506]. J Clin Oncol 2006;24(suppl 18):. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=40&abstractID=34300; cited January 12, 2013]
39. Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalido-mide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82:426-32.
40. Richardson P, Orlowski RZ, San Miguel J, et al. Risk of second primary malingnacies (spm) in relapsed/refractory multiple myeloma (rrmm) patients (pts) treated with lenalidomide and dexamethasone (len+dex): analysis of MM-009/010 spm incidence rate (ir). Haematologica 2011;96(suppl 1):S25.
41. Dimopoulos MA, Orlowski RZ, Niesvizky R, Lonial S, Brandenburg NA, Weber DM. Lenalidomide and dexametha-sone (len plus dex) treatment in relapsed/refractory multiple myeloma (rrmm) patients (pts) and risk of second primary malignancies (spm): analysis of MM-009/010 [abstract 8009]. J Clin Oncol 2011;2:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=102&abstractID=84539; cited January 12, 2013]
42. Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011;25:1620-6.
43. Dimopoulos MA, Hussein M, Swern AS, Weber DM. Long-term outcomes and safety of continuous lenalidomide plus dexametha-sone (len+dex) treatment in patients (pts) with relapsed or refrac-tory multiple myeloma (rrmm) [abstract]. Blood 2011;118:2929.
44. Zonder JA, Crowley JJ, Bolejack V, et al. A randomized Southwest Oncology Group study comparing dexamethasone (d) to lenalidomide plus dexamethasone (ld) as treatment of newly-diagnosed multiple myeloma (ndmm): impact of cytogenetic abnormalities on efficacy of ld, and updated overall study results [abstract 8521]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=55&abstractID=36278; cited January 12, 2013]
45. Zonder JA, Crowley J, Hussein M, et al. Extended results of Southwest Oncology Group protocol S0232: durable responses achieved with lenalidomide (l) plus high-dose dexamethasone (d) as first-line therapy for multiple myeloma. Haematologica 2011;96(suppl 1):S79.
46. Siegel DS, Jacobus S, Rajkumar SV, et al. Outcome with lenalidomide plus dexamethasone followed by early autolo-gous stem cell transplantation in the ecog E4A03 randomized clinical trial [abstract]. Blood 2010;116:38.
47. Jacobus S, Callander N, Siegel D, et al. Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ecog randomized trial of lenalidomide/high-dose dexa-methasone (rd) versus lenalidomide/low-dose dexamethasone (Rd) [abstract 370]. Haematologica 2010;95(suppl 2):149.
48. Jacobus SJ, Kumar S, Uno H, et al. Impact of high-risk clas-sification by fish: an Eastern Cooperative Oncology Group (ecog) study E4A03. Br J Haematol 2011;155:340-8.
49. Vesole DH, Jacobus S, Rajkumar SV, et al. Lenalidomide plus low-dose dexamethasone (ld): superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (ld) [abstract 308]. Blood 2010;116:308.
50. Harvey RD, Jacobus SJ, Rajkumar SV, Greipp PR, Lonial S. Renal function measures improve on lenalidomide and dexamethasone and compete with patient characteristics to predict lenalidomide dose density and hematologic toxicity: an E4A03 analysis [abstract]. Blood 2011;118:1882.
51. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. Blood 2012;119:933-9.
52. Palumbo A, Cavallo F, Di Raimondo F, et al. A phase 3 study comparing melphalan-prednisone-lenalidomide (mpr) with high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed patients with multiple myeloma (mm) [abstract]. Eur J Cancer 2011;47(suppl AS639):S639.
53. Palumbo A, Cavallo F, Hardan I, et al. Melphalan/prednisone/lenalidomide (mpr) versus high-dose melphalan and autolo-gous transplantation (MEL200) in newly diagnosed multiple myeloma (mm) patients < 65 years: results of a randomized phase iii study [abstract]. Blood 2011;118:3069.
54. Attal M. Lenalidomide (Revlimid) maintenance therapy for multiple myeloma after transplantation: the ifm 2005-02 trial, final analysis. Pharmacol Ther 2011;36:102.
55. Attal M, Lauwers-Cances V, Marit G, et al. Maintenance treat-ment with lenalidomide after transplantation for myeloma: final analysis of the ifm 2005-02 [abstract]. Blood 2010;116:310.
56. Kumar S, Flinn IW, Hari PN, et al. Novel three-and four-drug combinations of bortezomib, dexamethasone, cyclophospha-mide, and lenalidomide, for newly diagnosed multiple my-eloma: encouraging results from the multi-center, randomized, phase 2 evolution study [abstract 127]. Blood 2009;114:127.
57. Lonial S, Jakubowiak AJ, Jagannath S, et al. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma [abstract]. Blood 2011;118:303.
58. Hoyle M, Rogers G, Garside R, Moxham T, Stein K. The Clinical-and Cost-Effectiveness of Lenalidomide for Mul-tiple Myeloma in People Who Have Received At Least One Prior Therapy: An Evidence Review of the Submission from Celgene. Exeter, UK: Peninsula College of Medicine and Dentistry; 2008. [Available online at: http://www.hta.ac.uk/erg/reports/1746.pdf; cited January 2, 2011]
59. Mateos MV, Lopez-Corral L, Hernandez M, et al. Smoldering multiple myeloma (smm) at high-risk of progression to symptomatic disease: a phase iii, randomized, multicenter trial based on lenalidomide-dexamethasone (len-dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. [abstract 991]. Blood 2011;118:991.
60. McCarthy PL, Owzar K, Anderson K, et al. Phase iii intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (asct) for multiple myeloma (mm): calgb ecog bmt-cnt 100104. Hae-matologica 2011;96(suppl 1):S23.
61. Palumbo AP, Delforge M, Catalano J, et al. Incidence of second primary malignancy (spm) in melphalan-prednisone-lenalidomide combination followed by lenalidomide mainte-nance (mpr-r) in newly diagnosed multiple myeloma patients (pts) age 65 or older [abstract 8007]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=102&abstractID=82234; cited January 31, 2013]
62. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69.
63. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple my-eloma. N Engl J Med 2012;366:1782-91.
64. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81.
65. Guideline summary: use of epoetin and darbepoetin in patients with cancer-2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Oncol Pract 2008;4:48-52.
66. Shehata N, Walker I, Quirt K, Imrie K, Haynes AE, Trudeau M on behalf of the Hematology Disease Site Group. Treatment of Anemia with Erythropoietic Agents in Patients with Cancer-Adaption/Adoption of ash-asco Guidelines. Evidence-based series #6-11. Toronto, ON: Cancer Care Ontario; 2010.
67. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:2079-80.